These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 9046981)
1. Von Willebrand's disease. Ewenstein BM Annu Rev Med; 1997; 48():525-42. PubMed ID: 9046981 [TBL] [Abstract][Full Text] [Related]
2. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Castaman G; Federici AB; Rodeghiero F; Mannucci PM Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832 [TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
4. Von Willebrand's disease: case report and review of literature. Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ; Bonar R; Favaloro J; Koutts J Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [TBL] [Abstract][Full Text] [Related]
6. [Von Willebrand's disease]. Furlan M Schweiz Med Wochenschr; 1987 Nov; 117(46):1798-806. PubMed ID: 3122318 [TBL] [Abstract][Full Text] [Related]
8. Management of inherited von Willebrand disease in 2007. Federici AB; Mannucci PM Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477 [TBL] [Abstract][Full Text] [Related]
9. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Giannini S; Mezzasoma AM; Leone M; Gresele P Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology, diagnosis, and management of von Willebrand disease in India. Ghosh K; Shetty S Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205 [TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353 [TBL] [Abstract][Full Text] [Related]
12. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363 [TBL] [Abstract][Full Text] [Related]
13. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361 [TBL] [Abstract][Full Text] [Related]
14. [Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports]. Kleinschmidt S; Fuchs-Buder T; Wilhelm W; Seyfert UT; Mörsdorf S Anaesthesist; 2002 Oct; 51(10):825-34. PubMed ID: 12395174 [TBL] [Abstract][Full Text] [Related]
15. Rethinking the diagnosis of von Willebrand disease. Favaloro EJ Thromb Res; 2011 Jan; 127 Suppl 2():S17-21. PubMed ID: 21193108 [TBL] [Abstract][Full Text] [Related]
16. Molecular genetics of von Willebrand disease. Mazurier C; Ribba AS; Gaucher C; Meyer D Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650 [TBL] [Abstract][Full Text] [Related]
17. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681 [TBL] [Abstract][Full Text] [Related]
18. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
19. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
20. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]